Liquid Letro / Letrozole 30mL 2.5mg/mL
Letrozole controls estrogen levels
Aromatase inhibitor that effectively controls estrogen at very low application levels.
- Agitate bottle before each administration
- Not for human consumption
Letrozole (also known as Femara) is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery. Letrozole has been used for ovarian stimulation by fertility doctors since 2001 due to less chance of multiple gestation. It also shows promise in studies as a treatment for early onset gynecomastia.
Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Estrogens then bind to an estrogen receptor, which causes cells to divide.Letrozole prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids.
Letrozole acts as a nonsteroidal CYP19 (aromatase) inhibitor. It is also known to inhibit estradiol production in vitro in hamster ovarian tissue that is LH-stimulated. Letrozole has not been shown to have a significant effect on progesterone production up to 350 M. Letrazole has been shown to inhibit aldosterone production in vitro in rat adrenal tissue stimulated by ACTH. No significant effect has been seen on corticosterone production at 350 M. Letrozole has no effect on corticosterone or aldoterone levels in vivo in ACTH-treated rats.
CAS Number 112809-51-5
***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The products are for research purposes only.***